RPRX
Royalty Pharma Plc
NASDAQ: RPRX · HEALTHCARE · BIOTECHNOLOGY
$50.09
+1.21% today
Updated 2026-04-30
Market cap
$29.37B
P/E ratio
27.83
P/S ratio
12.35x
EPS (TTM)
$1.78
Dividend yield
1.77%
52W range
$31 – $50
Volume
3.2M
Royalty Pharma Plc (RPRX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
32.40%
Operating margin
57.70%
ROE
13.20%
ROA
5.15%
Debt/equity
1.38x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | — | — | — | — | — |
| 2007 | — | — | — | — | — |
| 2008 | — | — | — | — | — |
| 2009 | — | — | — | — | — |
| 2010 | $244000.00 | — | — | — | — |
| 2011 | — | — | — | — | — |
| 2012 | — | — | — | — | — |
| 2013 | — | — | — | — | — |
| 2014 | $0.00 | $-32.53M | — | — | — |
| 2015 | $1.65B | $581.43M | 100.00% | 48.07% | 35.19% |
| 2016 | $1.88B | $565.91M | 100.00% | 38.50% | 30.14% |
| 2017 | $1.60B | $1.21B | 100.00% | 58.81% | 75.72% |
| 2018 | $1.79B | $1.38B | 100.00% | 76.02% | 76.76% |
| 2019 | $1.81B | $2.35B | 100.00% | 144.59% | 129.45% |
| 2020 | $2.12B | $975.04M | 100.00% | 75.17% | 45.94% |
| 2021 | $2.29B | $619.73M | 100.00% | 62.49% | 27.07% |
| 2022 | $2.24B | $42.83M | 100.00% | 13.73% | 1.91% |
| 2023 | $2.35B | $1.13B | 100.00% | 63.37% | 48.20% |
| 2024 | $2.26B | $858.98M | 100.00% | 57.10% | 37.95% |
| 2025 | $2.38B | $770.95M | 100.00% | 65.58% | 32.42% |